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Background: High expression of constitutive histone γ-H2AX, a sensitive marker of DNA damage, might be
indicative of defective DNA repair pathway or genomic instability. 53BP1 (p53-binding protein 1) is a conserved
checkpoint protein with properties of a DNA double-strand breaks sensor. This study explores the relationship
between the clinical radiosensitivity of tumor patients and the expression/induction of γ-H2AX and 53BP1 in vitro.
Methods: Using immunostaining, we assessed spontaneous and radiation-induced foci of γ-H2AX and 53 BP1 in
peripheral blood mononuclear cells derived from unselected breast cancer (BC) patients (n=57) undergoing
radiotherapy (RT). Cells from apparently healthy donors (n=12) served as references.
Results: Non-irradiated cells from controls and unselected BC patients exhibited similar baseline levels of DNA
damage assessed by γ-H2AX and 53BP1 foci. At the same time, the γ-H2AX assay of in vitro irradiated cells revealed
significant differences between the control group and the group of unselected BC patients with respect to the
initial (0.5 Gy, 30 min) and residual (2 Gy, 24 h post-radiation) DNA damage. The numbers of 53BP1 foci analyzed in
35 BC patients were significantly higher than in controls only in case of residual DNA damage. A weak correlation
was found between residual foci of both proteins tested. In addition, cells from cancer patients with an adverse
acute skin reaction (grade 3) to RT showed significantly increased radiation-induced γ-H2AX foci and their
protracted disappearance compared to the group of BC patients with normal skin reaction (grade 0–1). The mean
number of γ-H2AX foci after 5 clinical fractions was significantly higher than that before RT, especially in clinically
radiosensitive patients.
Conclusions: The γ-H2AX assay may have potential for screening individual radiosensitivity of breast cancer patients.
Trial registration: http://www.krebshilfe.de/wir-foerdern.html
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Breast cancer (BC) is the common type of tumor in
females, accounting for approximately 21% of all cancer
cases in women worldwide [1]. Among BC patients 2%
have a strong genetic predisposition, caused by the
mutations in highly penetrant BRCA1 and BRCA2 genes
[2]. Because these genes cannot explain the overall
increased risk in the relatives of BC cases [3], it was
suggested that a substantial proportion of BC patients
may be predisposed to cancer through mutations in low* Correspondence: djuzenova_t@klinik.uni-wuerzburg.de
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distribution, and reproduction in any mediumpenetrance genes [4-6], which might be involved in
DNA damage processing and repair.
Several DNA damage repair pathways constitute a guard
system that protects cells against genetic instability and
tumorigenesis. Both genetic instability and impaired DNA
repair have been proposed as factors underlying increased
susceptibility to tumorigenesis (for reviews, see [7,8]). The
biological significance of genetic instability and DNA
repair mechanisms in cancer development is particularly
well illustrated by the autosomal recessive disorders, such
as Ataxia telangiectasia, Fanconi anemia and Nijmegen
breakage syndrome. These chromosome breakage syn-
dromes are characterized by defects in DNA repair, pre-
disposition to different forms of malignancy and increasedtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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syndromes, the deficient DNA repair capacity has been
proposed to be a predisposing factor in familial BC and in
some sporadic BC cases [10]. Genomic instability has also
been described for various hereditary cancers including
hereditary BC [3,11].
Genomic instability and DNA repair capacity have
been analyzed in numerous population-based studies
using a variety of assays that assess chromosomal aberra-
tions, sister chromatid exchanges, micronuclei, DNA
fragmentation by means of the Comet assay, etc. Some
of these studies have revealed reduced DNA repair
capacity in peripheral blood mononuclear cells (PBMCs,
exposed in vitro to ionizing radiation (IR) or UV) from
BC patients, as evaluated by the chromosome aberration
assay [10,12,13] as well as by the micronucleus test
[3,6,14]. In addition, histone γ-H2AX can serve as a
further useful marker of DNA integrity and repair [15].
As shown by [16], constitutive expression of histone γ-
H2AX may indicate disruption of the DNA damage re-
pair pathway and/or genetic instability. In that study, the
authors have observed a subset of patients with triple
negative breast cancer based on γ-H2AX positivity in
the formalin fixed tumor samples and embedded breast
cancer cell lines [16].
Furthermore, the kinetics of formation or loss of γ-
H2AX foci might be related to the efficiency of “repair”
of higher order chromatin organization [17]. By
counting γ-H2AX foci in blood lymphocytes, Rübe et al.
(2010) [18] found impaired DNA repair capacity in cells
from children with tumors [18]. At the same time, the
initial numbers of γ-H2AX foci after in vitro irradiation
were found very similar among the groups studied [18].
Moreover, Brzozowska et al. (2012) [19] found, by flow
cytometry, an increased expression of histone γ-H2AX
in irradiated blood lymphocytes from normal donors, as
compared to tumor patients [19]. But the difference was
not confirmed when γ-H2AX foci were counted by
fluorescence microscopy. A series of studies [18-24] used
histone γ-H2AX as a marker to predict the toxicity in
normal tissue during radiotherapy of tumor patients,
however, with contradictory outcomes. Thus, some of
the quoted studies [19,21-23] revealed no correlation be-
tween either acute or late side effects of radiation ther-
apy (RT) and expression of histone γ-H2AX. In contrast,
other workers [18,20] found that the disappearance of
histone γ-H2AX correlated with high-grade toxicity
from RT treatment. Henríquez-Hernández et al. (2011)
[24] also suggest that lower levels of initial DNA damage
may be associated with a lower risk of suffering from se-
vere late subcutaneous toxicity [24].
Despite extensive studies into the relationship between
cellular radiation tests, cancer risk and clinical radiation
reaction, a general opinion has not yet been formed. Thediscrepancies cited above prompted us to explore
whether the histone γ-H2AX assay is able to predict the
clinical radiation reaction of BC patients and to discrim-
inate them from healthy subjects. We examined both
baseline and radiation-induced DNA damage in PBMCs
from a group of 57 unselected BC patients compared
with a group of healthy subjects (n=12). PBMCs from a
small group (n=6) of BC patients with an adverse early
skin reaction to radiotherapy have also been retrospect-
ively analyzed. In addition to γ-H2AX, we analyzed the
foci of 53BP1 (p53-binding protein 1), a well-known sen-
sor protein of DNA damage [25]. DNA double-strand
breaks (DSB) attract the 53BP1 protein to the surround-
ing chromatin, where the 53BP1 is recruited by methyl-
ated H3 Lys 79 and signals chromatin/DNA damage [25]
in a γ-H2AX-dependent manner.
Materials and methods
Subjects
The assay was performed on PBMCs isolated from two
groups of individuals: (1) a group (n=57) of unselected
BC patients who were prospectively involved in the
study and their blood samples were collected before and
during (72 h after 5 clinical fractions) clinical radiation;
and (2) a group of apparently healthy donors (n=12),
mainly hospital personal. To our knowledge, none of the
healthy controls was previously exposed to radiation. All
patients and healthy donors were asked to complete a
questionnaire on their medical histories and lifestyles,
including genetic diseases, medication, alcohol consump-
tion, smoking (Additional file 1: Tables S1 and S2). Tumor
stage (Additional file 1: Table S1) was determined ac-
cording to the standard TNM criteria. This evaluation
yielded 3, 37, 15, 1, and 1 case(s) scored as stage DCIS, T1,
T2, T3, and T4, respectively (Additional file 1: Table S2).
Tumor patients receiving chemotherapy during RT were
excluded. The study was approved by the University of
Würzburg Ethics Committee and all patients and donors
gave informed written consent.
RT treatment of cancer patients was performed by
means of a 6 MV linear accelerator (Siemens Concord,
CA, USA) at a dose rate of 2 Gy/min. All BC patients
received a tangential irradiation of the whole breast, with
lateral and medial wedge fields. The regimen comprised
a total dose of 50 or 60 Gy with a fractionation dose of
2 Gy five times a week. The early skin reaction to RT
developing in the skin within the radiation field of the
breast was controlled at the end of RT and used as an
indicator for clinical radiosensitivity according RTOG
score [26].
Blood sampling and isolation of cells
PBMCs were separated from the heparinized blood samples
by density-gradient centrifugation using Ficoll-Histopaque
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the manufacturer's instructions. PBMCs were washed twice
with Ca2+- and Mg2+-free physiological phosphate-buffered
saline (PBS, Sigma D-8537) and finally resuspended in the
RPMI 1640 (Sigma R-8758) supplemented with 10% FBS,
glutamine (1 mM), and penicillin-streptomycin (100 U/ml
and 100 μg/ml, respectively), hereafter denoted as complete
growth medium (CGM), and incubated at 37°C in a
humidified atmosphere enriched with 5% CO2 until
irradiation.In vitro X-ray irradiation
The final cell density of isolated PBMCs was adjusted to
1 × 106 cells/ml and the samples were placed at 37°C in
a 5% CO2 incubator. X-irradiation (0.5 and 2 Gy) was
performed using a 6 MV Siemens linear accelerator
(Siemens Concord, CA, USA) at a dose rate of 2 Gy/min.0.0
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Figure 1 Comparison of histone γ-H2AX foci in PBMCs derived from c
by means of the histone γ-H2AX assay in non-irradiated (A) and in irradiate
compared to the cells from apparently healthy donors (circles). Initial (B), re
PBMCs after irradiation with 0.5 Gy (B, C) or 2 Gy (D) in vitro. Filled squares
indicates that the difference was not highly significant (p > 0.05).Non-irradiated cells were treated in similar way, but at a
zero radiation dose.
Immunofluorescence staining
A cell aliquot (2–3 × 105) of control or irradiated cells
was cytocentrifuged at various time points after IR on a
glass slide and fixed for 15 min in ice-cold methanol,
and then for 1 min in 100% acetone at −20°C. Slides
were washed three times for 5 min in PBS and blocked
with 4% FBS-PBS for 1 h at room temperature [27].
Blindly coded slides were incubated overnight at 4°C
with either anti-phospho-histone H2AX (Millipore,
Schwalbach, Germany, # 05–636), or anti-53BP1 (Novus
Biologicals, Cambridge, UK, NB 100–304) antibodies
followed by incubation with respective secondary anti-
bodies conjugated with Alexa Fluor 488 or 594 nm.
Slides were counterstained with 0.2 μg/ml of DAPI
(4’,6’-diamidino-2-phenylindole) in antifade solution2
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sidual (C - 0.5 Gy, 24 h, D - 2 Gy, 24 h) DNA damage were assessed in
represent the mean values (± SD) for the respective group. “n.s.”
Table 1 DNA damage measured by the histone γ-H2AX in PBMCs isolated from blood of apparently healthy donors (N)
and unselected breast cancer (BC) patients after exposure to 0.5 or 2 Gy of X-irradiation in vitro* or after 5 clinical
fractions (BC patients)
Subjecta Age
(years)
Sex Clinical status with respect to cancer, skin
reaction to RTb
0 Gy 0.5 Gy,
30’
0.5 Gy,
24 h
2 Gy,
24 h
72 h after 5 clinical
fractions
Apparently healthy donors
N-1 27 F n.d. 0.02 3.11 0.94
N-2 28 F n.d. 0.04 2.60 0.86
N-3 29 F n.d. 0.13 1.94 0.29 0.55
N-4 58 F n.d. 0.07 2.00 0.28 0.41
N-5 58 F n.d. 0.15 2.86 0.47 0.39
N-6 65 F n.d. 0.12 2.73 0.42 0.74
N-7 56 F n.d. 0.05 1.72 0.15 0.28
N-8 48 F n.d. 0.41 2.67 0.28 0.60
N-9 41 F n.d. 0.17 2.49 0.29 0.37
N-10 44 F n.d. 0.07 2.09 0.19 0.34
N-11 48 F n.d. 0.08 2.33 0.15 0.47
N-12 43 F n.d. 0.10 2.23 0.19 0.36
Mean 45 0.12 2.40 0.27 0.53
± SD 12 0.10 0.40 0.10 0.21
Breast cancer patients
BC-01 59 F BC, grade 3 0.70 3.29 2.59 0.32
BC-02 63 F BC, grade 1 0.62 2.39 2.93 0.57
BC-03 45 F BC, grade 0 0.92 2.87 3.93 0.67
BC-04 73 F BC, grade 3 0.42 4.50 2.61 0.66
BC-05 57 F BC, grade 1 0.07 5.48 2.50 0.49
BC-06 50 F BC, grade 1 0.27 4.77 1.72 0.56
BC-07 63 F BC, grade 2 0.46 5.32 3.65 0.75
BC-08 70 F BC, grade 2 0.84 5.49 4.47 0.64
BC-12 61 F BC, grade 3 0.25 4.71 2.26 0.57
BC-13 55 F BC, grade 3 0.32 5.34 3.11 0.83
BC-14 54 F BC, grade 2 0.14 3.75 1.18 0.19
BC-20 52 F BC, grade 1 0.32 3.77 1.95 1.06
BC-23 51 F BC, grade 1 0.12 2.67 2.25 0.77
BC-25 41 F BC, grade 0 0.44 4.99 1.27 0.30
BC-26 63 F BC, grade 1 0.21 3.62 1.92 0.35
BC-27 71 F BC, grade 1 0.14 3.31 0.92 0.57
BC-28 42 F BC, grade 0 0.10 4.29 1.29 0.35
BC-29 74 F BC, grade 1 0.22 3.7 1.12 0.28
BC-30 46 F BC, grade 2 0.05 3.39 0.77 0.32
BC-31 56 F BC, grade 2 0.01 1.95 0.95 0.27
BC-32 44 F BC, grade 2 0.08 2.98 1.08 0.28
BC-33 41 F BC, grade 3 0.19 3.43 0.92 0.29
BC-34 38 F BC, grade 2 0.10 3.22 0.86 0.28
BC-35 77 F BC, grade 2 0.07 3.23 0.91 0.06
BC-36 70 F BC, grade 1 0.06 2.72 0.81 0.18
BC-37 64 F BC, grade 0 0.03 2.90 0.48 0.19
BC-38 73 F BC, grade 1 0.08 2.37 0.48 0.20
BC-39 55 F BC, grade 1 0.01 2.05 0.13 0.31 0.43
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Table 1 DNA damage measured by the histone γ-H2AX in PBMCs isolated from blood of apparently healthy donors (N)
and unselected breast cancer (BC) patients after exposure to 0.5 or 2 Gy of X-irradiation in vitro* or after 5 clinical
fractions (BC patients) (Continued)
BC-40 77 F BC, grade 2 0.05 2.24 0.11 0.15 0.34
BC-41 54 F BC, grade 1 0.09 2.11 0.31 0.39 0.38
BC-42 49 F BC, grade 1 0.01 2.05 0.15 0.40 0.34
BC-43 62 F BC, grade 2 0.05 1.99 0.43 0.62 0.57
BC-44 59 F BC, grade 1 0.04 2.54 0.41 0.75 0.18
BC-45 51 F BC, grade 1 0.02 2.81 0.40 0.64 0.24
BC-46 62 F BC, grade 1 0.32 3.58 0.70 0.28 0.32
BC-47 30 F BC, grade 2 0.22 3.27 0.41 0.24 0.18
BC-48 71 F BC, grade 2 0.26 3.48 0.46 0.59 0.51
BC-49 46 F BC, grade 2 0.18 3.15 0.38 0.60 0.30
BC-50 48 F BC, grade 3 0.13 3.34 0.33 0.31 0.34
BC-51 57 F BC, grade 1 0.09 2.63 0.39 0.34 0.41
BC-52 62 F BC, grade 2 0.09 2.54 0.25 0.36 0.31
BC053 68 F BC, grade 2 0.09 2.23 0.20 0.34 0.16
BC-54 37 F BC, grade 1 0.14 2.28 0.25 0.47 0.4
BC-55 67 F BC, grade 1 0.08 2.73 0.41 0.4 0.27
BC-57 55 F BC, grade 1 0.11 2.68 0.3 0.76 0.38
BC-58 62 F BC, grade 1 0.06 2.62 0.31 0.6 0.32
BC-59 55 F BC, grade 1 0.07 1.85 0.22 0.41 0.36
BC-60 65 F BC, grade 2 0.11 3.32 0.42 0.54 0.43
BC-61 54 F BC, grade 2 0.04 2.09 0.25 0.52 0.43
BC-62 53 F BC, grade 2 0.06 0.06 0.19 0.14 0.38
BC-63 69 F BC, grade 1 0.09 2.65 0.34 0.59 0.4
BC-64 81 F BC, grade 1 0.1 2.65 0.39 0.36 0.27
BC-65 38 F BC, grade 2 0.15 2.01 0.31 0.67 0.31
BC-66 77 F BC, grade 1 0.14 2.29 0.3 0.64 0.27
BC-67 48 F BC, grade 1 0.14 2.61 0.45 0.71 0.36
BC-68 49 F BC, grade 2 0.1 2.48 0.22 0.53 0.27
BC-69 51 F BC, grade 1 0.26 2.25 0.2 0.53 0.16
Mean 57 0.18 3.07 0.32 1.11 0.39
± SD 12 0.19 1.04 0.12 1.01 0.19
*Each indicated DNA damage parameter represents the mean value obtained on the cells from a given individual. Bold fonts indicate the unselected BC patients
who revealed an adverse acute skin reaction to RT;
aCase number was according to our files;
bEarly skin reaction according RTOG score (Cox et al., 1995) [26]. RTOG grade: 1 - follicular, faint or dull erythema, dry desquamation; 2 - tender or bright
erythema, moderate edema; 3 - confluent, moist desquamation, pitting edema; 4 - ulceration, haemorrhage, necrosis.
Abbreviations used: N, normal; BC, breast cancer; F, female; n.d., not determined.
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ined using a Leica DMLB epifluorescence microscope (at
a 1000x magnification) coupled to a cooled CCD camera
(ColorView 12, Olympus Biosystems, Hamburg, Germany).
Camera control and image acquisition were done with
image analysis software (Olympus Biosystems, Hamburg,
Germany). The foci were counted by eye in 500 cells per
each treatment condition, no threshold for γ-H2AX or
53BP1 was set. The cells with apoptotic morphologies or
cells with bright nuclei (intense, complete coverage of the
nuclei with foci staining) were excluded from the analyses.Because the wide-field microscopic setup used here does
not allow three-dimensional microscopy with Z-planning,
two-dimensional images were captured from the focal
plane.
Statistics
Data are presented as mean (± SD). Mean values were
compared by the Student's t-test or one way ANOVA.
The threshold of statistical significance was set at p < 0.05.
Statistics was performed with the program Origin 8.5
(Microcal, Northampton, MS, USA).
Table 2 DNA damage measured by 53BP1 in PBMCs isolated from blood of apparently healthy donors (N) and
unselected breast cancer (BC) patients after exposure to 0.5 or 2 Gy of X-irradiation in vitro* or after 5 clinical
fractions (BC patients)
Subjecta Age (years) Sex Clinical status with respect to
cancer, skin reaction to RTb
0 Gy 0.5 Gy, 30’ 0.5 Gy, 24 h 2 Gy, 24 h 72 h after 5
clinical fractions
Apparently healthy donors
N-3 29 F n.d. 0.71 2.47 0.99 1.47
N-4 58 F n.d. 0.68 2.83 0.96 1.37
N-5 58 F n.d. 0.41 2.65 1.16 1.25
N-6 65 F n.d. 0.35 2.48 1.07 1.73
N-7 56 F n.d. 0.53 2.26 0.66 0.76
N-8 48 F n.d. 0.38 2.32 0.98 1.36
N-9 41 F n.d. 0.32 2.10 0.96 1.04
N-10 44 F n.d. 0.50 2.46 0.79 1.02
N-11 48 F n.d. 0.48 2.60 0.81 1.20
N-12 43 F n.d. 0.38 2.42 0.67 0.80
Mean 45 0.47 2.46 0.91 1.20
± SD 12 0.13 0.20 0.16 0.29
Breast cancer patients
BC-01 59 F BC, grade 3 0.13 0.85 n.d. 1.84 1.73
BC-04 73 F BC, grade 3 0.15 1.24 n.d. 2.61 1.68
BC-12 61 F BC, grade 3 0.11 1.19 n.d. 2.18 0.95
BC-13 55 F BC, grade 3 0.35 2.47 n.d. 2.86 1.23
BC-33 42 F BC, grade 3 0.35 0.87 n.d. 2.78 1.60
BC-39 55 F BC, grade 1 0.32 2.56 0.75 1.41 0.90
BC-40 77 F BC, grade 2 0.61 2.43 0.62 0.61 0.78
BC-41 54 F BC, grade 1 0.97 2.36 1.11 1.34 0.91
BC-42 49 F BC, grade 1 0.19 2.48 0.76 1.68 0.80
BC-43 62 F BC, grade 2 0.33 1.99 0.92 1.58 0.42
BC-44 59 F BC, grade 1 0.24 2.08 1.25 2.16 0.58
BC-45 51 F BC, grade 1 0.20 1.73 1.20 2.12 0.77
BC-46 62 F BC, grade 1 0.33 2.73 1.34 0.56 0.74
BC-47 30 F BC, grade 2 0.26 2.57 1.38 0.98 0.65
BC-48 71 F BC, grade 2 0.79 3.34 1.16 1.96 0.93
BC-49 46 F BC, grade 2 0.49 3.19 1.19 1.84 0.62
BC-50 48 F BC, grade 3 0.68 3.29 0.88 1.39 0.68
BC-51 57 F BC, grade 1 0.71 2.82 0.93 1.43 0.50
BC-52 62 F BC, grade 2 0.66 2.48 0.87 1.50 0.59
BC-53 68 F BC, grade 2 0.98 2.81 0.84 1.37 0.55
BC-54 37 F BC, grade 1 0.65 2.29 0.84 1.49 0.95
BC-55 67 F BC, grade 1 0.73 2.35 0.89 1.50 0.71
BC-57 55 F BC, grade 1 0.86 3.40 0.89 2.04 0.69
BC-58 62 F BC, grade 1 0.52 3.25 0.95 2.05 0.57
BC-59 55 F BC, grade 1 0.45 2.69 0.82 1.62 0.88
BC-60 65 F BC, grade 2 0.65 2.86 0.97 1.61 0.49
BC-61 54 F BC, grade 2 0.54 2.66 0.88 1.63 0.96
BC-62 53 F BC, grade 2 0.49 2.65 0.77 1.37 0.72
BC-63 69 F BC, grade 1 0.62 2.73 1.05 1.81 0.58
BC-64 81 F BC, grade 1 0.6 2.62 0.84 1.37 0.47
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Table 2 DNA damage measured by 53BP1 in PBMCs isolated from blood of apparently healthy donors (N) and
unselected breast cancer (BC) patients after exposure to 0.5 or 2 Gy of X-irradiation in vitro* or after 5 clinical
fractions (BC patients) (Continued)
BC-65 38 F BC, grade 2 0.58 2.35 0.95 1.70 0.87
BC-66 77 F BC, grade 1 0.46 2.46 0.83 1.44 0.57
BC-67 48 F BC, grade 1 0.43 1.87 0.86 1.52 0.66
BC-68 49 F BC, grade 2 0.42 2.49 0.65 1.73 0.73
BC-69 51 F BC, grade 1 0.41 2.00 0.84 1.70 0.49
Mean 57 0.49 2.40 0.94 1.70 0.80
± SD 12 0.23 0.63 0.19 0.49 0.32
*Each indicated DNA damage parameter represents the mean value obtained on the cells from a given individual. Bold fonts indicate the unselected BC patients
who revealed an adverse acute skin reaction to RT;
aCase number was according to our files;
bEarly skin reaction according RTOG score (Cox et al., 1995) [26]. RTOG grade: 1 - follicular, faint or dull erythema, dry desquamation; 2 - tender or bright
erythema, moderate edema; 3 - confluent, moist desquamation, pitting edema; 4 - ulceration, haemorrhage, necrosis.
Abbreviations used: N, normal; BC, breast cancer; F, female; n.d. indicates not determined.
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The damage to DNA and its repair kinetics were evalu-
ated up to 24 h after exposure to 0.5 Gy or 2 Gy of X-
rays in vitro. The extent of DNA damage was assessed
by counting the number of histone γ-H2AX foci, a0.4
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Figure 2 Comparison of 53BP1 foci in PBMCs derived from control do
mean number of 53BP1 foci in non-irradiated (A) and irradiated (B-D) PBM
cells from apparently healthy donors (circles). For further details, see legendsensitive marker of DNA double-strand breaks (DSBs)
[28]. The mean data from 500 nuclei were determined
for the cell samples from each tested individual (Figure 1).
The means for each tested group of individuals are also
shown in Figure 1.2
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to Figure 1.
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http://www.ro-journal.com/content/8/1/98The data on initial, residual and background DNA
damage measured by histone γ-H2AX for each indivi-
dual, as well as the age, sex and grade of skin reaction to
RT are given in Table 1, from which the following trends
are obvious (see also Figure 1). Although non-irradiated
cells of some cancer patients exhibited noticeably lower
baseline amounts of DNA damage, i.e. in the range of
controls, the mean value of background DNA damage
(Figure 1A) was higher (0.2±0.2 foci/nucleus) in the BC
patient group, as compared to the group of healthy indi-
viduals (0.1±0.1). However, the difference does not reach
statistical significance, which may be in part due to the
strong interindividual variability. In contrast, after irradi-
ation in vitro, the γ-H2AX assay did reveal significant
differences between the two groups in terms of their ini-
tial (Figure 1B, 0. 5 Gy, 30 min) and residual levels of
DNA damage (Figure 1D, 2 Gy, 24 h).
In addition, the foci numbers of 53BP1, a sensor of
DNA damage [25], were compared between 10 healthy0
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Filled squares represent the mean values (± SD) for the respective group. “n.s.” insamples and 35 samples from BC patients (Table 2). As
seen in Figure 2, the mean expression levels of this
marker protein were very similar in two groups, except
for the time point of 24 h after irradiation with 2 Gy. As
suggested by a reviewer, we compared the expression of
γ-H2AX and 53BP1 per nucleus at different time and
radiation doses. Judging from the correlation coefficients
given in Additional file 1: Figure S1, there was a weak
correlation between residual amounts of γ-H2AX and
53BP1 foci (Additional file 1: Figure S1, parts C and D),
but no correlation (Additional file 1: Figure S1, parts A
and B) was found between background and induced
(0.5 Gy, 30 min) γ-H2AX and 53BP1 foci.
Out of 57 prospectively recruited BC patients, six
exhibited an increased early skin reaction to RT (grade 3
according RTOG score, see Table 1, cases BC01, BC04,
BC12, BC13, BC33 and BC48). Based on the clinical skin
reaction of radiotherapy patients we analyzed retrospec-
tively the initial, residual and background DNA damage2
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nd irradiated (B-D) PBMCs derived from normally-reacting BC patients
to cells from apparently healthy donors (circles). Initial (B), residual DNA
were assessed in PBMCs after irradiation with in vitro (B, C) or in vivo (D).
dicates that the difference was not highly significant (p > 0.05).
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http://www.ro-journal.com/content/8/1/98measured by histone γ-H2AX between the groups of BC
patients with normal (RTOG grade 0 and 1, n=31) and
an adverse (RTOG grade 3, n=6) skin reaction to RT
compared with the healthy donors (Figure 3). As seen in
Figure 3A, background DNA damage in PBMCs from
BC patients with increased clinical skin reaction was
higher than that from control donors. The induced
DNA damage 30 min after in vitro application of 0.5 Gy
(Figure 3B) and the residual DNA damage (Figure 3C,
2 Gy, 24 h) were higher in both BC groups than that in
the cells from controls. However, blood samples taken
from BC patients 72 h after the fifth clinical radiation
dose showed mostly similar histone γ-H2AX expression
in both groups of patients (Figure 3D).
In order to elucidate the observed increase in the
mean numbers of γ-H2AX foci in cells derived from
hypersensitive cancer patients, we further analyzed the
distributions of γ-H2AX foci within different cell sam-
ples. Figure 4 shows exemplarily the histograms of γ-
H2AX foci per nucleus in cells from BC patients with
normal (BC-25, BC-28, BC-57, top histograms) and ad-
verse (BC-01, BC-04, BC-12, BC-13, bottom histograms)
clinical sensitivity to RT. The PBMCs taken before clin-
ical RT were irradiated in vitro with 2 Gy and allowed to
repair 24 h post-IR, fixed and stained for histone γ-
H2AX. We found that the fraction of γ-H2AX foci-
negative cells in samples from normal sensitive BC
patients was about 40%, whereas only 14% of cells were
γ-H2AX negative in the samples from hypersensitive BC
patients at this time point. The mean number of foci per0 1 2 3 4
0
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200
Skin reaction to R
γ-H2AX fo
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Figure 4 Foci γ-H2AX distribution in PBMCs derived from normally-reacti
distributions within cell samples from cancer patients with normal (grade 0–1, to
to RT. Cells were analyzed for γ-H2AX focus 24 h after irradiation with 2 Gy in vitnucleus in the samples from normally-reacting BC pa-
tients was about 1.0. Compared to the cells from
normally-reacting BC patients, the histograms of cells
from clinically sensitive BC patients were shifted to higher
values, showing in average of about 2–3 foci per nucleus.
In addition, as mentioned in the Materials and Methods,
blood samples were withdrawn from all recruited BC
patients after 5 clinical fractions and analyzed for γ-H2AX
and 53BP1 foci. As seen in Figure 5A, the mean number
of γ-H2AX foci per patient’s sample after 5 clinical
fractions was significantly higher (0.39±0.19) than before
RT (0.18±0.19). A group of BC patients with adverse skin
reaction to RT showed an even higher number of γ-H2AX
foci (0.50±0.22).
The quantification of 53BP1 foci (Figure 5B) was
conducted in a smaller patients’ group (n=35 vs. n=57
tested for γ-H2AX), which however, contained all clinic-
ally sensitive BC patients (n=6) who showed an adverse
skin reaction to RT. Comparison of the mean number of
53BP1 foci per patient’s sample after 5 clinical fractions
revealed a significantly increased foci numbers after clin-
ical irradiation (0.8±0.3 vs. 0.5±0.2 before RT) for the
whole group tested (n=35). A subset of BC patients with
adverse skin reaction to RT showed much higher num-
ber of 53BP1 foci (1.3±0.4) after 5 clinical fractions.
As suggested by a referee, we performed correlation
analysis between tumor stage and the expression of γ-
H2AX and 53BP1 foci. As seen in Additional file 1:
Figure S2, tumor stages DCIS, T1 and T2 exhibited simi-
lar levels of expression of both γ-H2AX and 53BP1. In5 6 7 8 9 10
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ci/nucleus
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Figure 5 Effect of clinical radiation on the expression of γ-H2AX
and 53BP1 foci in blood lymphocytes. DNA damage assessed by
means of the histone γ-H2AX (A) and 53BP1 (B) assays in non-irradiated
(down triangles) and in clinically irradiated (right triangles) PBMCs derived
from unselected BC patients compared with BC patients with an adverse
(grade 3) skin reaction to RT (asterisks). Filled squares represent the mean
values (± SD) for the respective group.
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counted only once, no statistical analysis could be done.
Discussion
In this study, peripheral blood cells isolated from (1) unse-
lected BC patients, and (2) healthy individuals were ana-
lyzed for their DNA damage using the histone γ-H2AX
assay. During or after RT a small group of patients (n=6)
showed an adverse early skin reaction to RT. The analysis
of non-irradiated cell samples did not reveal any differ-
ences in the background DNA damage levels between the
group of healthy donors and unselected BC patients
(Figure 1A). However, if the radiotherapy patients’ groupwas split into the subgroups according to their acute clin-
ical skin reaction (RTOG), the background DNA damage
in cells derived from hypersensitive BC patients was sig-
nificantly higher than that in healthy donors (Figure 3A).
Irradiation in vitro of the samples from BC patients
revealed an increased (p < 0.05) amount of γ-H2AX foci
30 min (Figure 1B, 0.5 Gy) and 24 h post-IR (Figure 1D,
2 Gy). The differences in γ-H2AX foci amounts 30 min
and 24 h post-IR with 0.5 Gy and 2 Gy, respectively
became even higher (p<0.0005) if the groups of healthy
donors and the patients with an adverse clinical reaction
to RT (Figure 3B, 3C) were compared. In addition, the
mean background value of γ-H2AX in the samples of
hypersensitive BC patients was significantly higher (p<0.05)
than in control group. Interestingly, retrospective analysis
of the groups of BC patients with normal (n=31) and an
adverse (n=6) clinical reaction to RT revealed statistically
significant differences in the induction (Figure 3B) and
repair (Figure 3C) of DNA damage 30 min and 24 h post-
IR with 0.5 and 2 Gy in vitro.
Our results disagree with those of Vasireddy et al.
(2010) [23] who have found no differences in levels of
both basal and radiation-induced DNA damage in cells
from tumor patients with increased clinical radiosensi-
tivity and healthy controls [23]. The reasons for the dis-
crepancy might reside in the patients’ and controls’
cohorts, cancer stage, treatment prior to blood sampling,
arbitrary determined cut-off values, experimental proto-
cols, methods of foci quantification (flow cytometry vs.
fluorescence microscopy) as well as in interlaboratory
variability. Moreover, in contrast to the present and sev-
eral other studies [18,20,21], which analyzed primary
PBMCs or T-cells [19], the paper of Vasireddy et al.
(2010) [23] used lymphoblastoid cell lines (LCLs) derived
from cells of tumor patients [23]. Besides this, the quanti-
fication of histone γ-H2AX foci by fluorescence micros-
copy appears to differ greatly between laboratories. Thus,
the background values of about 0.07-0.08 γ-H2AX foci
pro lymphocyte in non-irradiated cells reported by
Fleckenstein et al. (2012) [21] are some 3 times lower than
the values presented here in Figure 1A.
As mentioned before, we found the differences in the
induction and disappearance of γ-H2AX foci between
the groups of patients with an adverse skin reaction to
RT and normally-reacting patients or healthy donors
(Figure 3B, 3C). These results disagree with the findings
of some studies [19,20] who observed, by flow cytome-
try, a higher fluorescence of histone γ-H2AX in irradi-
ated cells from healthy donors, as compared to the
patients with severe side effects after RT. At the same
time, the protracted rate of disappearance of histone γ-
H2AX foci found in our study in cells of radiation-
sensitive cancer patients corroborate well the data of
Bourton et al. (2011) [20]. It may be argued that in the
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45±12 years) was younger than the group of BC patients
(mean age of 57±12 years). The literature on age de-
pendence of γ-H2AX formation, however, seems quite
controversial. Based on the comparison of two donors
groups differing markedly in age (31–45 vs. 50–72 years),
Firsanov et al. (2011) [29] conclude that the dynamics of
γ-H2AX formation is independent of age [29]. In con-
trast, Sedelnikova et al. (2008) found [30], by comparing
two groups with a much larger deviation (21–30 years
vs. 60–72 years) in age than our groups, that the por-
tions (about 30%) of cells containing γ-H2AX foci in
older individuals (60–72 years) was higher than in youn-
ger individuals (about 20%). But the incidence of γ-
H2AX foci in response to IR was found to be age inde-
pendent [30].
Since fortunately only a minority (about 5%) of RT pa-
tients develop either acute or late radiotoxic responses
during or after RT [31], a cohort of 57 prospectively
recruited BC patients in our study was too small to re-
veal several radiation-sensitive patients. Among them,
we observed a small group (n=6) of patients exhibiting
early skin radiotoxicity during or shortly after RT. Even
so, there was a correlation of radiation response in vivo
with increased initial and/or residual DNA damage level
after irradiation in vitro, as well as with increased back-
ground DNA damage in a γ-H2AX assay compared to
healthy controls. Furthermore, we found differences in
the initial and residual DNA damage between irradiated
cells from tumor patients with normal and those with an
adverse clinical sensitivity to RT (Figure 3B, 3C, first and
second data sets). In addition, samples derived from BC
patients after 5 clinical radiation fractions showed an in-
creased amount of γ-H2AX foci compared with that
obtained before RT (Figure 5).
The second marker of DNA DSB formation studied
here was the 53BP1 protein. Given that the γ-H2AX test
reveals a DSB-induced protein modification and the
53BP1 foci indicate the accumulation of a DSB-modified
chromatin protein [25,32], both types of radiation-
induced foci should be very similar at all measurement
points and mostly overlapping in fluorescence images
[33]. In our hands, however, the 53BP1 assay was less
sensitive than that for histone γ-H2AX in case of
endogeneous (0 Gy) and induced (0.5 Gy, 30 min) foci.
There may be at least two reasons for the observed dis-
crepancy between two assays. Firstly, the quantification
of γ-H2AX and 53BP1 foci was done in partially overlap-
ping but different patients’ cohorts. Secondly, for detec-
tion of γ-H2AX and 53BP1 we used commercially
available antibodies which were very different in their
immunological properties, i.e. highly specific monoclonal
antibodies against γ-H2AX and less selective polyclonal
antibodies against 53BP1. Therefore, it cannot beexcluded that if both antibody preparations were of the
same specificity the tests would yield similar results. Be-
sides this, the 53BP1 analysis was done for a much
smaller patient’s group (n=35), as compared to γ-H2AX
assay (n=57). Nevertheless, residual (24 h post-IR) foci
of both proteins were found to be weakly correlated
(Figure S1).
In conclusion, prospectively recruited BC patients
showed on average increased initial and residual DNA
damage levels measured by histone γ-H2AX, as com-
pared with the healthy group. However, due to a large
interindividual variability, it was not possible to discrim-
inate BC patients from healthy individuals. But a minor
(n=6) group of retrospectively identified BC patients
with an adverse skin reaction to RT (analyzed separately
from normally-reacting BC patients), showed striking
differences by the γ-H2AX assay with respect to healthy
individuals. The γ-H2AX assay was also able to identify
BC patients with normal clinical reaction to RT on the
basis of the induced and residual DNA damage, but not
on the basis of background DNA damage. A larger study
would be necessary in order to investigate the complex
mechanisms behind the normal tissue radiotoxicity.
Additional file
Additional file 1: Table S1. Demographic characteristics of patients
undergoing radiation therapy. Table S2. Demographic characteristics of
patients undergoing radiation therapy (Summary). Figure S1.
Correlational analysis of mean γ-H2AX and 53BP1 foci counts from 500
nuclei per sample. Non-irradiated and irradiated with 0.5 and 2 Gy
lymphocytes were fixed 30 min or 24 post-IR. The expression of both
proteins was analyzed simultaneously at each time and IR points for
n=30 blood samples (BC39-BC69). Figure S2. Correlation between the γ-
H2AX/53BP1 foci expression and tumor staging. Peripheral lymphocytes
were prepared from the blood samples derived from breast cancer
patients. Foci counting for γ-H2AX and 53BP1 foci were performed in
non-irradiated and irradiated with 0.5 Gy samples 30 min post-IR derived
from 57 and 39 patients, respectively.
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